ERBB2 and breast carcinoma: Trastuzumab emtansine, contrarily, has shown clinically meaningful results with an absolute increase in invasive disease-free survival at 3 years of 11.3% compared with trastuzumab in patients with HER2-positive breast cancer who do not achieve a pCR following standard anti-HER2-based chemotherapy.